uniQure Offers Initial Top-Line Data From Dose-Combo Study Of AMT-061 In Patients With Hemophilia B: 'All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31%'
Benzinga Newsdesk